



# Financial Tear Sheet

## Corporate Profile

MyoKardia is a clinical stage biopharmaceutical company pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. MyoKardia’s initial focus is on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. MyoKardia has used its precision medicine platform to generate a pipeline of therapeutic programs for the chronic treatment of the two most prevalent forms of heritable cardiomyopathy —hypertrophic cardiomyopathy, or HCM, and dilated cardiomyopathy, or DCM.

## Stock Information

### MYOK (Common Stock)

Exchange	NASDAQ GS (US Dollar)
Price	<b>\$36.85</b>
Change (%)	▼ 0.35 (0.94%)
Volume	265,178
52 Week Low	\$10.55
Market Cap	\$1,317,057,177
Rolling EPS	-0.74
PE Ratio	0
Shares Outstanding	35,741,036

Data as of 11/20/17 4:00 p.m. ET



## Recent Press Releases

11/15/17

Preclinical Studies with MyoKardia’s Mavacamten Demonstrate Evidence of Reduced Contractility and Improved Left Ventricular Compliance

11/13/17

MyoKardia Presents Data from Study of Machine Learning Algorithm Intended to Identify Obstructive Hypertrophic Cardiomyopathy Using a Wearable Biosensor

11/02/17

MyoKardia Reports Third Quarter 2017 Financial Results and Operational Progress









## Upcoming Events

There are currently no events scheduled.

## SEC Filings

<< First | Previous | Next | Last >>

Filing Date	Form	Description	Filing Group	Downloads
11/08/17	4	Statement of changes in beneficial ownership of securities	3,4,5	   
11/03/17	4	Statement of changes in beneficial ownership of securities	3,4,5	   
11/03/17	4	Statement of changes in beneficial ownership of securities	3,4,5	   
11/03/17	4	Statement of changes in beneficial ownership of securities	3,4,5	   
11/03/17	10-Q	Quarterly report which provides a continuing view of a company's financial position	Quarterly Filings	   
11/02/17	8-K	Report of unscheduled material events or corporate event	Current Reports	   
10/06/17	4	Statement of changes in beneficial ownership of securities	3,4,5	   
10/04/17	4	Statement of changes in beneficial ownership of securities	3,4,5	   

09/29/17	4	Statement of changes in beneficial ownership of securities	3,4,5				
09/29/17	4	Statement of changes in beneficial ownership of securities	3,4,5				

[<< First](#) | [Previous](#) | [Next](#) | [Last >>](#)

## Corporate Governance

Tassos Gianakakos      Chief Executive Officer

Jonathan Fox, M.D., Ph.D. Chief Medical Officer

Jake Bauer                      Vice President, Business Development and Business Operations

Ingrid Boyes                      Senior Vice President, Human Resources

Steven Chan                      Vice President, Corporate Controller

Joseph Lambing, Ph.D. Senior Vice President, Nonclinical and Pharmaceutical Development

Robert McDowell                      Senior Vice President of Drug Discovery

Iris Roth, Ph.D.                      Vice President, Program Team Leader